Mingxi Tang

811 total citations
34 papers, 623 citations indexed

About

Mingxi Tang is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Mingxi Tang has authored 34 papers receiving a total of 623 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Molecular Biology, 7 papers in Oncology and 6 papers in Cancer Research. Recurrent topics in Mingxi Tang's work include MicroRNA in disease regulation (3 papers), Autism Spectrum Disorder Research (3 papers) and Ion channel regulation and function (3 papers). Mingxi Tang is often cited by papers focused on MicroRNA in disease regulation (3 papers), Autism Spectrum Disorder Research (3 papers) and Ion channel regulation and function (3 papers). Mingxi Tang collaborates with scholars based in China, Japan and United States. Mingxi Tang's co-authors include Tomoyuki Shirai, Satoru Takahashi, Makoto Asamoto, Kumiko Ogawa, Azman Seeni, Shinya Sato, Shugo Suzuki, Satoshi Sugiura, Aya Naiki‐Ito and Pornsiri Pitchakarn and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and International Journal of Molecular Sciences.

In The Last Decade

Mingxi Tang

30 papers receiving 608 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mingxi Tang China 14 280 106 87 84 80 34 623
Haiyan Han China 15 368 1.3× 75 0.7× 84 1.0× 75 0.9× 33 0.4× 32 692
Antonio Malorni Italy 15 567 2.0× 73 0.7× 104 1.2× 79 0.9× 33 0.4× 28 954
Mingzhu Fang United States 13 510 1.8× 83 0.8× 78 0.9× 37 0.4× 46 0.6× 30 906
Raju Khatri United States 7 570 2.0× 59 0.6× 54 0.6× 56 0.7× 43 0.5× 10 879
Saber Ghazizadeh Darband Iran 16 362 1.3× 131 1.2× 70 0.8× 55 0.7× 35 0.4× 20 767
Hye Joung Choi United States 17 500 1.8× 121 1.1× 36 0.4× 52 0.6× 87 1.1× 21 1.0k
Mei-Hui Tai United States 13 376 1.3× 67 0.6× 192 2.2× 62 0.7× 32 0.4× 19 799
Alessio Lepore Italy 9 315 1.1× 88 0.8× 85 1.0× 38 0.5× 57 0.7× 14 695
Stephen L. Slocum United States 9 930 3.3× 153 1.4× 56 0.6× 123 1.5× 43 0.5× 10 1.2k
Shyamali Mukherjee United States 15 293 1.0× 72 0.7× 39 0.4× 205 2.4× 73 0.9× 55 759

Countries citing papers authored by Mingxi Tang

Since Specialization
Citations

This map shows the geographic impact of Mingxi Tang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mingxi Tang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mingxi Tang more than expected).

Fields of papers citing papers by Mingxi Tang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mingxi Tang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mingxi Tang. The network helps show where Mingxi Tang may publish in the future.

Co-authorship network of co-authors of Mingxi Tang

This figure shows the co-authorship network connecting the top 25 collaborators of Mingxi Tang. A scholar is included among the top collaborators of Mingxi Tang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mingxi Tang. Mingxi Tang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ji, Quan, et al.. (2025). Resveratrol targeting MDM2/P53/PUMA axis to inhibit colonocyte apoptosis in DSS-induced ulcerative colitis mice. Frontiers in Pharmacology. 16. 1572906–1572906.
2.
Wang, Jing, et al.. (2025). HER2 and hormone receptor conversion after neoadjuvant therapy for breast cancer. Frontiers in Oncology. 15. 1522460–1522460. 1 indexed citations
3.
Dong, Ping, Yunqing Mei, Mingxi Tang, et al.. (2024). A synthetic peptide, derived from neurotoxin GsMTx4, acts as a non-opioid analgesic to alleviate mechanical and neuropathic pain through the TRPV4 channel. Acta Pharmaceutica Sinica B. 15(3). 1447–1462.
4.
5.
Chen, Shi, et al.. (2024). Neuroimaging techniques, gene therapy, and gut microbiota: frontier advances and integrated applications in Alzheimer’s Disease research. Frontiers in Aging Neuroscience. 16. 1485657–1485657. 3 indexed citations
6.
Luo, Jing, et al.. (2023). Recent progress in the effect of ferroptosis of HSCs on the development of liver fibrosis. Frontiers in Molecular Biosciences. 10. 1258870–1258870. 10 indexed citations
7.
Zhu, Mingwei, Wen‐Xiong Chen, Jing Luo, et al.. (2023). A novel mutation in intron 1 of Wnt1 causes developmental loss of dopaminergic neurons in midbrain and ASD-like behaviors in rats. Molecular Psychiatry. 28(9). 3795–3805. 8 indexed citations
8.
Wang, Haitao, et al.. (2023). Roles of tissue-resident immune cells in immunotherapy of non-small cell lung cancer. Frontiers in Immunology. 14. 1332814–1332814. 8 indexed citations
9.
Zhang, Yulin, et al.. (2023). The microbial dark matter and “wanted list” in worldwide wastewater treatment plants. Microbiome. 11(1). 59–59. 17 indexed citations
10.
Chen, Wen‐Xiong, Bin Liu, Xiaoli Xiong, et al.. (2022). De novo mutations within metabolism networks of amino acid/protein/energy in Chinese autistic children with intellectual disability. Human Genomics. 16(1). 52–52. 10 indexed citations
11.
Hu, Jiajia, et al.. (2021). Clinical and Prognostic Implications of 1p/19q, IDH, BRAF, MGMT Promoter, and TERT Promoter Alterations, and Expression of Ki-67 and p53 in Human Gliomas. Cancer Management and Research. Volume 13. 8755–8765. 10 indexed citations
12.
Xu, Mingliang, et al.. (2020). Blocking retrograde axonal transport of autophagosomes contributes to sevoflurane-induced neuron apoptosis in APP/PS1 mice. Acta Neurologica Belgica. 121(5). 1207–1215. 6 indexed citations
13.
Li, Hui, Jie Xu, Guangming Wang, et al.. (2019). The neuropeptide GsMTx4 inhibits a mechanosensitive BK channel through the voltage-dependent modification specific to mechano-gating. Journal of Biological Chemistry. 294(31). 11892–11909. 14 indexed citations
14.
Ogawa, Kumiko, Pornsiri Pitchakarn, Shugo Suzuki, et al.. (2012). Silencing of connexin 43 suppresses invasion, migration and lung metastasis of rat hepatocellular carcinoma cells. Cancer Science. 103(5). 860–867. 47 indexed citations
15.
Takahashi, Satoru, Hiroji Uemura, Azman Seeni, et al.. (2012). Therapeutic targeting of angiotensin II receptor type 1 to regulate androgen receptor in prostate cancer. The Prostate. 72(14). 1559–1572. 31 indexed citations
16.
Takahashi, Satoru, et al.. (2011). Hypertension is positively associated with prostate cancer development in the TRAP transgenic rat model. Pathology International. 61(4). 202–209. 5 indexed citations
17.
Takahashi, Satoru, Azman Seeni, Satoshi Sugiura, et al.. (2009). Suppression of prostate cancer in a transgenic rat model via γ‐tocopherol activation of caspase signaling. The Prostate. 69(6). 644–651. 50 indexed citations
18.
Cho, Young‐Man, Shinji Takahashi, M. Asamoto, et al.. (2007). Suppressive effects of antiandrogens, finasteride and flutamide on development of prostatic lesions in a transgenic rat model. Prostate Cancer and Prostatic Diseases. 10(4). 378–383. 9 indexed citations
19.
Tang, Mingxi, Kumiko Ogawa, Makoto Asamoto, et al.. (2007). Protective effects of citrus nobiletin and auraptene in transgenic rats developing adenocarcinoma of the prostate (TRAP) and human prostate carcinoma cells. Cancer Science. 98(4). 471–477. 77 indexed citations
20.
Kandori, Hitoshi, Shugo Suzuki, Makoto Asamoto, et al.. (2005). Influence of atrazine administration and reduction of calorie intake on prostate carcinogenesis in probasin/SV40 T antigen transgenic rats. Cancer Science. 96(4). 221–226. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026